The investment provides CaaMTech with capital to advance compounds from its library into clinical trials ISSAQUAH, Wash., Sept. 08, 2021 (GLOBE NEWSWIRE) — CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing round, led by Noetic Fund. The oversubscribed round of funding will be deployed to support CaaMTech’s industry…


Previous articleRed Light Holland Closes Majority Stake in Acadian Exotic Mushrooms, Partnering with Leading Canadian Fresh and Dried Mushroom Producers on East Coast Facility
Next articleMYND Life Sciences Announces Closing of Fully Subscribed $3 Million Convertible Debenture Unit Offering